Peter J.M. Valk

25.2k citations

190 papers · 10.0k indexed · 3 hit papers · h-index 49

Hematology top 0.05%
- Acute Myeloid Leukemia Research 131
- Chronic Myeloid Leukemia Treatments 29
Genetics top 0.2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 33
- Chronic Lymphocytic Leukemia Research 16
Cancer Research top 1%
- Cancer Genomics and Diagnostics 22
Molecular Biology top 1%
- Epigenetics and DNA Methylation 25
- Protein Degradation and Inhibitors 24
- Retinoids in leukemia and cellular processes 14
Immunology top 2%

Co-authors: Bob Löwenberg Ruud Delwel Claudia Erpelinck-Verschueren H. Berna Beverloo Roel G.W. Verhaak Bas J. Wouters Mathijs A. Sanders Sanne Lugthart
Cited by: Hematology Genetics Cancer Research
Journals: Blood (65 papers)Haematologica (12 papers)British Journal of Haematology (8 papers)
Partner nations: Netherlands United States Germany

In The Last Decade

Peter J.M. Valk

182 papers receiving 9.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Peter J.M. Valk

Since Specialization

Citations

This map shows the geographic impact of Peter J.M. Valk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J.M. Valk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J.M. Valk more than expected).

Fields of papers citing papers by Peter J.M. Valk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J.M. Valk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J.M. Valk. The network helps show where Peter J.M. Valk may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peter J.M. Valk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter J.M. Valk Line = papers co-authored together Peter J.M. Valk links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Mutational Landscape and Depth of Response in Patients with Acute Myeloid Leukemia (AML) Treated with Magrolimab in Combination with Venetoclax and Azacitidine Compared to Placebo Blood ·Lisa D. Johnson,Stephanie Y. Kang,Н.С. Холод,Marlen Metzner,Santos Ar,François G. Kavelaars,Yoga Priawan,Anne E. Lawson,Kenneth J. Caldwell,Peter J.M. Valk,Paresh Vyas	2024	1
2	High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML) Cell Death and Disease ·Jan Danyłow,W. Cary Hill,Marcus M. Schittenhelm,Gunnar Blumenstock,Balázs Győrffy,Serena Fazio,敏孝小木曽,Andreas Ahrens,Vitor C. Ribeiro,徐宝仪,François G. Kavelaars,César Nombela‐Arrieta,Falko Fend,Peter J.M. Valk,Daniel C. Christoph,Kerstin Maria Kampa-Schittenhelm	2024	1
3	A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction British Journal of Haematology ·Toby Carnat,Diego A. Pereira‐Martins,Xingcan Zhang,Peng Yeong Pin,Isabel Weinhäuser,寿也保高,Juan Luiz Coelho‐Silva,Carolina Hassibe Thomé,Jesús Navarro,Emanuele Ammatuna,Gerwin Huls,Peter J.M. Valk,Jan Jacob Schuringa,Eduardo Magalhães Rego	2024	3
4	Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML Blood Advances ·Zarovnyĭ Av,Tim Grob,Melissa Rijken,François G. Kavelaars,Daniel Vachard,Gert J. Ossenkoppele,Markus G. Manz,(unknown),(unknown),Bob Löwenberg,Peter J.M. Valk	2024	2
5	Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel American Journal of Hematology ·Farhad Ravandi,Jacqueline Cloos,Francesco Buccisano,Richard Dillon,Konstanze Döhner,Sylvie Freeman,Christopher S. Hourigan,G. J. Ossenkoppele,Gail J. Roboz,Marion Subklewe,Christian Thiede,Mike Lyman,Peter J.M. Valk,Adriano Venditti,Andrew H. Wei,Roland B. Walter,Michael Heuser	2023	10
6	Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML Blood ·Roger Mulet‐Lazaro,Susanne Hagedorn,Claudia Erpelinck-Verschueren,Eric M. Bindels,Mathijs A. Sanders,Carlo Vermeulen,Ivo Renkens,Peter J.M. Valk,Ari Melnick,Jeroen de Ridder,Michael Rehli,Claudia Gebhard,Ruud Delwel,Bas J. Wouters	2021	13
7	Disruption of CSF-1R signaling inhibits growth of AML with inv(16) Blood Advances ·Alexander Simonis,Norman F. Russkamp,Jan Mueller,C. Matthias Wilk,Mattheus H. E. Wildschut,Renier Myburgh,Vincent Cheylan,Lawrence Farmer,Stefan Balabanov,Peter J.M. Valk,Alexandre Theocharides,Markus G. Manz	2021	7
8	Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification Blood Advances ·Inge van der Werf,Anna Wojtuszkiewicz,Manja Meggendorfer,Stephan Hütter,Constance Baer,Martijn W. Heymans,Peter J.M. Valk,Wolfgang Kern,Claudia Haferlach,Jeroen J. W. M. Janssen,Gert J. Ossenkoppele,Jacqueline Cloos,Torsten Haferlach	2021	23
9	Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation The Journal of Pathology Clinical Research ·Paul G. Kemps,Konnie M. Hebeda,Steven T. Pals,Robert M. Verdijk,King H. Lam,Annette H. Bruggink,E. Jeziorski,Azadiyan Shahram,Koen de Heer,Tom Schinkel,Peter J.M. Valk,Pim Mutsaers,Mark‐David Levin,Pancras C.W. Hogendoorn,Astrid G. S. van Halteren	2020	30
10	Secondary CNL after SAA reveals insights in leukemic transformation of bone marrow failure syndromes Blood Advances ·M. Satish Varma,S.H. Curnow,Pontus Lundberg,Alexandar Tzankov,Martina Kleber,Jörg Halter,D. Ben Nsib,Peter J.M. Valk,Ivo P. Touw,Jakob Passweg,Beatrice Drexler	2020	2
11	Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations Blood ·Jonas S. Jutzi,Kwang Yeul Lyu,Reşat Aktan,S Kaiser,Doris Steinemann,Mathijs A. Sanders,Adil S. A. Al Hinai,Annelieke Zeilemaker,刘童,M. Layden,Dennis Y. C. Leung,Konrad Aumann,Wei Wang,Emmanuel Raffoux,Bruno Cassinat,Lars Bullinger,Brigitte Schlegelberger,Peter J.M. Valk,Heike L. Pahl	2019	20
12	Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe European Journal Of Haematology ·O. Selivanenko,Noortje Thielen,Jeroen J. W. M. Janssen,Mels Hoogendoorn,直子下尾,Peter J.M. Valk,Otto Visser,Jan J. Cornelissen,Peter E. Westerweel	2017	3
13	INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia Leukemia ·Irakli Dzneladze,María Rosa Randazzo,John F. Woolley,Meong Hi Son,闫咏梅,F. Vazeille,Zakhar Rozlach,Doron Goldbarsht,Anooshiravan Hami,Anne Hakem,Narmin Ibrahimova,Andrea Arruda,Bob Löwenberg,Peter J.M. Valk,Mark D. Minden,Leonardo Salmena	2015	43
14	Detection of CEBPA Double Mutants in Acute Myeloid Leukemia Using a Custom Gene Expression Array Genetic Testing and Molecular Biomarkers ·Martin H. van Vliet,Laura Denisse Chavarria Zuniga,吉岡正隆,Jaap Brand,Mary Sandbach,Henk E. Viëtor,Bob Löwenberg,Peter J.M. Valk,Erik H. van Beers	2013	4
15	Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid Leukemias Cancer Research ·Brynn T. Kvinlaug,文祐庄司,Lars Bullinger,Mukundhan Ramaswami,Christopher Sears,郭魏魏,Stanley E. Lazic,Rachel Okabe,Axel Benner,Benjamin H. Lee,Thiago Magalhães Lessa,Peter J.M. Valk,Ruud Delwel,Scott A. Armstrong,Hartmut Döhner,D. Gary Gilliland,Brian J.P. Huntly	2011	37
16	High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia Blood ·Hendrik J.M. de Jonge,Peter J.M. Valk,Nic J.G.M. Veeger,Arja ter Elst,Monique L. den Boer,Jacqueline Cloos,Válerie de Haas,Marry M. van den Heuvel‐Eibrink,Gertjan J.L. Kaspers,C. Michel Zwaan,Willem A. Kamps,Bob Löwenberg,Eveline S.J.M. de Bont	2010	74
17	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity Blood ·Erdogan Taskesen,Lars Bullinger,Andrea Corbacioglu,Mathijs A. Sanders,Claudia Erpelinck-Verschueren,Bas J. Wouters,Chiara Armeni,Frédérik Damm,Jürgen Krauter,Arnold Ganser,Richard F. Schlenk,Bob Löwenberg,Ruud Delwel,Hartmut Döhner,Peter J.M. Valk,Konstanze Döhner	2010	262
18	Significance of Murine Retroviral Mutagenesis for Identification of Disease Genes in Human Acute Myeloid Leukemia Cancer Research ·Stefan J. Erkeland,Roel G.W. Verhaak,Peter J.M. Valk,Ruud Delwel,Bob Löwenberg,Ivo P. Touw	2006	19
19	Evaluating the Effectiveness of TDM and Public Awareness Programs for the US 101 Highway Reconstruction Project in San Luis Obispo, California Peter J.M. Valk,J. Eichler	2005	1
20	SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. PubMed ·Primo N. Lara,David I. Quinn,Kim Margolin,Frederick J. Meyers,Jeff Longmate,Paul Frankel,Philip C. Mack,D.A. Potapova,Peter J.M. Valk,K. W. Lee,Antoni BronisÅaw Przygienda,Theodore Wun,Robert C. Gosselin,Weijian Yuan,Paul H. Gumerlock,Heinz Josef Lenz,James H. Doroshow,David R. Gandara	2003	51

About Peter J.M. Valk

Peter J.M. Valk is a scholar working on Hematology, Genetics and Cancer Research, having authored 190 papers that have together received 10.0k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (131 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (33 papers), Chronic Myeloid Leukemia Treatments (29 papers), Epigenetics and DNA Methylation (25 papers), Protein Degradation and Inhibitors (24 papers), Cancer Genomics and Diagnostics (22 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Retinoids in leukemia and cellular processes (14 papers). The work is most often cited by research in Hematology (6.2k citations), Genetics (2.1k citations) and Cancer Research (1.6k citations). Peter J.M. Valk has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Bob Löwenberg, Ruud Delwel, Claudia Erpelinck-Verschueren, H. Berna Beverloo, Roel G.W. Verhaak, Bas J. Wouters, Mathijs A. Sanders, Sanne Lugthart, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani and Peter J. van der Spek. Their work appears in journals such as Blood, Haematologica, British Journal of Haematology, Blood Advances and HemaSphere.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact